Skip to main content
main-content

Tipp

Weitere Artikel dieser Ausgabe durch Wischen aufrufen

01.11.2012 | original article | Ausgabe 21-22/2012

Wiener klinische Wochenschrift 21-22/2012

The significance of early treatment of exudative age-related macular degeneration: 12 months’ results

Zeitschrift:
Wiener klinische Wochenschrift > Ausgabe 21-22/2012
Autoren:
MD Birgit Weingessel, MD Gregor Hintermayer, MD Saskia M. Maca, MD Renate Rauch, MD Prim. Univ.-Doz. Dr. Pia Veronika Vecsei-Marlovits

Summary

Background

To assess whether the period between initial symptoms and therapy with ranibizumab in patients with choroidal neovascularization (CNV) influences visual outcome after a follow-up of 12 months.

Methods

Fifty patients with CNV were retrospectively split into three groups depending on the duration of visual symptoms: group I: < 1 month, group II: 1–6 months, and group III: > 6 months. Best-corrected visual acuity (BCVA) and central retinal thickness (CRT) were recorded at baseline, 2, 6, and 12 months. Patients received two initial intravitreal injections of 0.5 mg ranibizumab at baseline and reinjections as needed.

Results

The mean time span between initial symptoms and treatment was 66 ± 63 days. A longer duration of visual symptoms was significantly correlated with a lower BCVA at baseline, but also after 6 and 12 months.

Conclusions

Shorter duration of visual symptoms prior to treatment is associated with a better visual outcome.

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Literatur
Über diesen Artikel

Weitere Artikel der Ausgabe 21-22/2012

Wiener klinische Wochenschrift 21-22/2012 Zur Ausgabe

MUW resarcher of the month

Researcher of the Month

mitteilungen der gesellschaft der ärzte in Wien

Mitteilungen November 2012